Regentis Biomaterials Ltd. is a healthcare company specializing in regenerative medicine, with a focus on orthopedic tissue repair solutions. The company develops therapies designed to restore function in damaged or diseased cartilage and bone, targeting patients with painful joint conditions, particularly in the knee. Its core technology is the Gelrin platform, a degradable hydrogel implant engineered to support the regeneration of native tissue rather than simply replacing it. Gelrin is composed of polyethylene glycol diacrylate and denatured fibrinogen, forming a biocompatible matrix used in minimally invasive procedures. The company’s lead product, GelrinC, is a cell-free, off-the-shelf implant that is cured in situ within the knee to treat articular cartilage injuries. Operating within the medical instruments and supplies segment of the healthcare sector, Regentis Biomaterials serves orthopedic specialists and healthcare providers seeking advanced biomaterial-based solutions for joint preservation. Founded in 2004 and headquartered in Israel, it contributes to the growing market for regenerative orthopedic treatments.